Hot Life Science Investor Mandate 2: Venture Philanthropy Targets Neuromuscular Diseases

26 Jul

The venture philanthropy arm of a larger organization is currently looking for new companies in the life science space to invest in, and anticipates on investing in at least two new firms this year. The firm has an evergreen structure, meaning that funds come directly from its parent organization, and can be deployed as needed. The fund has over $100 million in total assets currently, and was allotted $4 million in 2013 for new investments, and typically makes equity investments ranging from $500,000 to $3 million.

The venture arm is currently looking for firms in the biotech therapeutics space. They are especially interested in companies that are developing therapeutics that treat diseases that fall within the realm of neuromuscular diseases. There about 40 different diseases within this category, but some of the specific areas of interest for the firm include multiple sclerosis and ALS, but they will consider therapeutics treating any indication within this subsector. They invest internationally, and will consider firms based in the US, as well as those based anywhere else around the world.

Primarily investing in pre-revenue companies, the firm has no criteria in terms of revenue or EBITDA. The firm will invest in firms that have products ranging from proof of concept in phase I to phase III.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: